Biotech investing has become an increasingly popular in recent years. Whether you’re new to stem cell stocks or you’ve been around the block, now could be a good time to place your bets. The stock market had its largest point drop in recent history on March 9, 2020. On March 12 and March 16, there were two more record-setting point drops. Even though the market has recovered since then, market prices remain attractive across many sectors.
Furthermore, stem cell companies have received substantial support for their use as living therapeutics against COVID-19 induced respiratory complications, such as ARDS. Given these conditions, an intriguing niche within biotech investing is stem cell stocks.
What Are Stem Cells?
Stem cells are undifferentiated cells that have the capacity to both differentiate and multiply into the 200 cells types that form a human being. In total, the human body is composed of an estimated 30 trillion cells, making stem cells extremely important to human development. Stem cells are also found in plants and animals.
Stem cells are the master cells in your body, and they can multiply in one of two ways. First, they can form more stem cells like themselves. Second, they can differentiate into specialized cell types, such as muscles cells, bloods cells, or brain cells, for example.
Stem Cell Stocks for 2021
Below is an list of all publicly traded stem cell stocks, listed alphabetically by their ticker symbol from “A” to “Z.” As you can see, there are nearly 40 publicly traded stem cell stocks for you to consider.
1. ADR-Autolus Therapeutics-NASDAQ
Autolus Therapeutics focuses on T-cell therapies for cancer patients.
2. ALPMY-Astellas Pharma-NASDAQ
Astellas is a biotech company dealing with cancer, specifically bladder cancer. They also import, export, and develop pharmaceutical products.
Arthersys is hoping to treat ischemic stroke, neurological disease, cardiovascular problems, and immune and inflammatory diseases.
Biocardia is a company that is involved with medicine for cardiovascular issues.
5. BCLI-BrainStorm Cell Therapeutics-NASDAQ
They have a wide array of products looking to fight ALS and other neurodegenerative diseases. such as MS, Huntington’s Disease, and Parkinson’s among others.
6. BSEM-Biostem Technologies Inc-OTC
BioStem Technologies develops amniotic membrane and umbilical cord tissue derived products for use in regenerative medicine, including: RHEO™, OROPRO™, VENDAJE™ and VENDAJE™ OPTIC.
7. BLUE-bluebird bio-NASDAQ
Bluebird Bio develops gene therapies.
8. BPSR-Organicell Regenerative Medicine Inc-OTC
Organicell is an integrated exosome therapeutics company. It is focused on ground-breaking research in the field of nanotechnology and is pursuing exosomes and other micro vesicles as the next frontier in stem cell-based therapeutics.
This company is developing stem cell treatments for disc degeneration in chronic back pain. They’re also looking into treating metabolic disorders.
10. CAPR-Capricor Therapeutics-NASDAQ
They discover, develop, and commercialize first-class therapeutics in the biological field.
11. CBMG-Cellular Biomedicine Group-NASDAQ
They develop immunotherapies for cancer patients and also develop stem cell therapies for degenerative problems. They’re also looking to treat osteoarthritis.
12. CCEL-Cryo-Cell International-OTCQB
CCEL is hoping to make advances in regenerative medicine with the cryo-preservation of stem cells. Their technology uses umbilical cord cells.
13. CELG-Celgene Corporation-NASDAQ
They develop and commercialize medicines for inflammatory disorders and cancer.
14. CLBS-Caladrius Biosciences-NASDAQ
Caladrius has three different products to treat autoimmune and cardiovascular diseases.
15. CYP-Cynata Therapeutics LTD-ASE
They have their own technology using mesenchymal stem cells.
16. CYTX-Cytori Therapeutics-NASDAQ
Cytori Therapeutics deals in specialty therapeutics combining nanoparticle and proprietary cell therapy platforms. They want to treat degenerative and oncologic conditions.
17. FATE-Fate Therapeutics INC.-NASDAQ
Fate Therapeutics develops programmed cellular immunotherapies, including induced pluripotent stem cell (iPSC) derived immunotherapies.
18. GERN-Geron Corporation-NASDAQ
Geron develops technology dealing with hematologic myeloid malignancies. They also specialize in therapeutic oncology products.
19. GMDA-Gamida Cell-NASDAQ
Gamida Cell is hoping to treat rare hematologic problems as well as blood cancers. They’re also looking to help bone marrow, transplant patients.
Kadimastem is a biotech company that commercializes and develops embryonic stem cell products.
21. KOOL-Cesca Therapeutics-NASAQ
Cesca Therapeutics wants to deliver automated technologies for cell-based therapeutics. They’re also engaged in immune-oncology automation and clinical biobanking.
22. LCTX-Lineage Cell Therapeutics-NASDAQ
This company develops novel cell therapies at the clinical level.
Medtronic provides stem cell technology to treat a broad range of medical conditions and diseases.
24. MESO-Mesoblast Limited-NASDAQ
Mesoblast is focused on regenerative stell cell treatments for cardiovascular disease, back pain, and inflammatory ailments.
Orgenesis develops and manufactures services in the gene and stem cell industry.
Osirus deals with a broad range of injuries and medical issues. Some of them include burns, bone grafts, and regeneration.
27. PSTI-Pluristem Therapeutics-NASDAQ
Pluristem develops placenta based off the shelf products. They are looking to treat radiation damage, ischemia, and other inflammatory problems.
28. RGS-Regeneus Ltd-ASX
Regeneus is an Australian clinical-stage company developing a novel cellular therapies, with an initial focus is on osteoarthritis (OA), musculoskeletal disorders, neuropathic pain and dermatology.
RepliCel specializes in stem cell-based approaches to hair, skin, and tendon regeneration.
30. SGMO-Sangamo Therapeutics-NASDAQ
Sangamo Therapeutics is a gene therapy pipeline that also focuses on gene editing
31. SNCA-Seneca Biopharma-NASDAQ
Deals with novel treatments of unmet medical needs.
32. STML-Stemline Therapeutics-NASDAQ
Stemline Therapeutics is solely focused on developing technologies and treatments to attack cancer cells.
33. THMO-ThermoGenesis Holdings-NASDAQ
They are developing stem cell processing technologies for stem cell and gene therapy.
This company deals with stem cell technology for immune diseases and inflammation.
35. TKPHF-Takeda Pharmaceuticals-OTC
The largest biopharmaceutical company in Asia.
36. USRM-US Stem Cell-OTC
US Stem Cell hopes to help treat and prevent a variety of degenerative diseases through ongoing research.
Vericel is focused on tissue collection, treating burn patients, and dealing with cartilage deficiencies of the knees.
38. VTGN-VistaGen Therapeutics-NASDAQ
VistaGen is hoping to develop commercialized entities for stem cells of the heart, liver, blood, and cartilage.
39. XINT-Xintela AB-NASDAQ
Xintela has developed a novel stem cell product platform, XSTEM, based on a versatile integrin marker technology that gives a range of regulatory and functional advantages compared to other stem cell products. The company is focused on using its technology for the treatment of osteoarthritis (OA), wound healing, and acute respiratory distress syndrome (ARDS).
How to Invest in Stem Cell Stocks
Investing in the stem cell market can be lucrative, risky, and volatile. That’s because it is a high-risk, high reward industry. After considering your risk tolerance, you’ll be ready to identify promising companies in which to invest.
First, you will want to consider the types products being developed, the IP the company has secured, and any approvals issued by regulatory bodies. Next, you’ll want to consider the company’s financials, their operational costs, and cash on hand to weather a downturn. Once you’re done your due diligence, you’ll be ready to place your bets on specific stem cell stocks.
Are there any stem cell stocks that are missing from this list? Share them in the comments and we’ll get them added.
*Disclaimer: Neither the author, nor any BioInformant employees, own the stocks mentioned in this article. This article does not constitute financial advice. Please consult with a qualified financial adviser or certified public accountant (CPA) prior to making any investment decisions.